Vaccine Nanoparticles for Protection Against HIV Infection

Aikins, Marisa; Bazzill, Joseph; Moon, James J.

doi:10.2217/nnm-2016-0381

Cited by 26 publications

(19 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This necessitates the urgent need for the development of a prophylactic vaccine against HIV. The most recent and promising HIV vaccine RV144 is in the phase III trial [156] . IgG antibodies raised against V1V2 loop were inversely correlated with the risk of infection in the clinical trial of RV144 [157] .…”

Section: Nanovaccines For Hivmentioning

confidence: 99%

Advancements in prophylactic and therapeutic nanovaccines

et al. 2020

View full text Add to dashboard Cite

Section: Nanovaccines For Hivmentioning

confidence: 99%

Advancements in prophylactic and therapeutic nanovaccines

et al. 2020

View full text Add to dashboard Cite

“…Advances in vaccine development via ligand delivery or creation of virus‐like particles have led to several promising treatments for a range of viral infections including HIV‐1, HCV, hepatitis B virus, human papillomavirus, and influenza. Several reviews on the topic detail the current advances (Aikins, Bazzill, & Moon, ; Singh et al, ; Sulczewski, Liszbinski, Romao, & Rodrigues Junior, ).…”

Section: Nanoparticles To Mimick Viruses: Potential Therapeutic Targets?mentioning

confidence: 99%

Masters of manipulation: Viral modulation of the immunological synapse

Bayliss

Piguet

2018

Cellular Microbiology

View full text Add to dashboard Cite

In order to thrive, viruses have evolved to manipulate host cell machinery for their own benefit. One major obstacle faced by pathogens is the immunological synapse. To enable efficient replication and latency in immune cells, viruses have developed a range of strategies to manipulate cellular processes involved in immunological synapse formation to evade immune detection and control T-cell activation. In vitro, viruses such as human immunodeficiency virus 1 and human T-lymphotropic virus type 1 utilise structures known as virological synapses to aid transmission of viral particles from cell to cell in a process termed trans-infection. The formation of the virological synapse provides a gateway for virus to be transferred between cells avoiding the extracellular space, preventing antibody neutralisation or recognition by complement. This review looks at how viruses are able to subvert intracellular signalling to modulate immune function to their advantage and explores the role synapse formation has in viral persistence and cell-to-cell transmission.

show abstract

“…Nanoparticle presentation of antigens offers the ability to formulate vaccines containing multiple proteins and adjuvants targeting specific immune cells, and more effective uptake by antigen presenting cells. [91–94]…”

Section: Five-year Viewmentioning

confidence: 99%

Pneumococcal whole-cell and protein-based vaccines: changing the paradigm

Pichichero

2017

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction. Epidemiologic evaluations of Streptococcus pneumoniae nasopharyngeal (NP) colonization and pneumococcal disease suggest that newer serotypes in future formulations of pneumococcal conjugate vaccines (PCVs) are needed and there may need to be continued reformulations because there are many new emerging serotypes expressed by pneumococci. Areas Covered: Mechanisms of protection by next-generation whole-cell vaccine (WCV) and/or multi-component pneumococcal purified protein vaccines (PPVs) in development for prevention of pneumococcal infections. Expert Commentary: A long-term strategy for prevention of pneumococcal disease will likely include WCV and PPVs. However these vaccines will impact disease pathogenesis in a different manner than PCVs. Prevention of pneumococcal NP colonization should not be expected, nor is it desirable because risks for NP colonization by other replacement organisms into the ecological niche vacated by all pneumococci may have consequences. The expression biology of capsule and surface protein antigens are phase dependent. Therefore, the immune response will be different and the mechanism of protection divergent. WCVs and PPVs may be alternative strategies in low income developing countries to protect against invasive disease and reduce NP carriage load.

show abstract

Vaccine Nanoparticles for Protection Against HIV Infection

Cited by 26 publications

References 77 publications

Advancements in prophylactic and therapeutic nanovaccines

Advancements in prophylactic and therapeutic nanovaccines

Masters of manipulation: Viral modulation of the immunological synapse

Pneumococcal whole-cell and protein-based vaccines: changing the paradigm

Contact Info

Product

Resources

About